Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
99mtc-radiolabelled tiotropium
- Development stage
- Unknown
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Inhalation
01
Overview
99mTc-radiolabelled tiotropium is a radiolabelled version of tiotropium used for research and diagnostic purposes to study lung deposition patterns. Tiotropium itself is a long-acting muscarinic antagonist (LAMA) bronchodilator that works by blocking M1, M2, and M3 muscarinic acetylcholine receptors in the lungs, preventing acetylcholine binding. This action leads to bronchodilation, decreased mucous gland secretions, and reduced airway inflammation. The radiolabelled version allows researchers to track the distribution and deposition of the drug in the lungs using gamma scintigraphy.
- Other names
- radiolabeled tiotropium
02
Targets
M1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)CHRM3 (M3)
Beyond the preview
Go deeper on 99mtc-radiolabelled tiotropium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 99mtc-radiolabelled tiotropium.